论文部分内容阅读
目的观察宣肺平喘、化痰祛瘀法对稳定期慢性阻塞性肺疾病(COPD)患者临床症状及生活质量的影响。方法将60例COPD稳定期患者随机分为治疗组和对照组,各30例,两组均给予舒弗美缓释片和沐舒坦片,治疗组加服宣肺平喘、化痰祛瘀中药。两组疗程均为30天。在治疗前及治疗后14天和1个月采用临床症状评分表及生活质量量表对患者临床症状及生活质量进行评估。结果治疗组总有效率为93.33%,对照组为83.33%,治疗组疗效优于对照组(P<0.05)。治疗组治疗后14天与治疗前比较,生活质量量表中焦虑心理症状评分差异统计学有统计学意义(P<0.05);治疗组治疗后30天与治疗前比较,日常生活能力、抑郁心理状态及焦虑心理症状评分差异有统计学意义(P<0.01)。治疗30天后,治疗组日常生活能力、社会活动能力、焦虑心理状态与对照组同期差异有统计学意义(P<0.01)。结论以宣肺平喘、化痰祛瘀立法的中药复方可以改善COPD稳定期患者的临床症状,提高患者生活质量。
Objective To observe the effects of Xuanfei and asthma, Phlegm and Blood Stasis on clinical symptoms and quality of life in patients with chronic obstructive pulmonary disease (COPD). Methods Sixty patients with stable COPD were randomly divided into treatment group and control group, with 30 cases in each group. Both groups were treated with Shumeimei sustained-release tablets and mucosolvan tablets. The treatment group received Xuanfei Asthma, Phlegm and Blood Stasis . Two groups of treatment are 30 days. Clinical symptoms and quality of life were evaluated before treatment and 14 days and 1 month after treatment by clinical symptom score scale and quality of life scale. Results The total effective rate was 93.33% in the treatment group and 83.33% in the control group. The curative effect in the treatment group was better than that in the control group (P <0.05). After treatment for 14 days, the scores of anxiety and psychological symptom scores in the quality of life scale in the treatment group were statistically significant (P <0.05). Compared with those before treatment, the daily living ability, depression psychology There were significant differences in status and anxiety psychological symptom scores (P <0.01). After 30 days of treatment, the daily living ability, social activity ability and anxiety state in the treatment group were significantly different from those in the control group (P <0.01). Conclusions The traditional Chinese medicine compound prescription, which takes the method of promoting lung and clearing asthma and resolving phlegm and stasis, can improve the clinical symptoms of stable COPD patients and improve the quality of life of patients.